ArticleFrontiers in microbiology2026
Exploring the potential of gut microbiota metabolites in the treatment of endometriosis through network pharmacology and Mendelian randomization.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Studies have shown that dysregulation of the gut microbiota (GM) plays a crucial role in the development of endometriosis (EMs). Study aimed to investigate the potential of protective GM metabolites in treating EM through network pharmacology and Mendelian randomization (MR), opening new avenues for targeted therapeutic strategies. Methods: All data were sourced from publicly available databases. Biomarkers linked to protective GM metabolites in EMs were identified employing MR study (with GM as the exposure and EMs as the outcome), differential expression analysis, machine learning, and gene expression analyses. Key metabolites associated with these biomarkers were identified through the gutMGene database. A network connecting biomarkers, key metabolites, and key microbes was constructed. Subsequently, drug similarity for the key metabolites was assessed, and molecular docking studies were performed to evaluate potential therapeutic interactions. Finally, reverse transcription quantitative PCR (RT-qPCR) analyses were conducted to further investigate the expression of biomarkers in clinical samples. Results: The MR study identified 5 key protective microbiota (such as genus. Conclusion: This study identified AOC3, FABP4, and NEK2 as potential EMs biomarkers associated with gut microbiota-derived metabolites. However, the proposed microbiota-metabolite-biomarker network requires further experimental validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.